Atherosclerosis risk factors: the possible role of homocysteine

P C Choy1, D Mymin, Q Zhu

  • 1The Lipid Research Group, Faculty of Medicine, University of Manitoba, Winnipeg, Canada.

Insights

Elevated homocysteine levels increase cholesterol production and apolipoprotein B-100 secretion in liver cells. This finding provides a mechanism linking high homocysteine to atherosclerosis and coronary artery disease.

Area of Science:

  • Cardiovascular Science
  • Biochemistry
  • Metabolic Disease

Background:

  • Atherosclerosis, a leading cause of death, involves coronary artery wall thickening and plaque formation.
  • Plaque rupture can cause thrombosis, leading to heart attack and stroke.
  • Over 250 factors are linked to coronary artery disease, with a recent focus on homocysteine.

Purpose of the Study:

  • To investigate the mechanism by which elevated homocysteine levels contribute to atherosclerosis.
  • To explore the effects of homocysteine on cholesterol synthesis and apolipoprotein secretion in liver cells.

Main Methods:

  • Human hepatoma cells (HepG2) were incubated with 4 mM homocysteine.
  • Cholesterol production and apolipoprotein B-100 secretion were measured.
  • The role of HMG-CoA reductase in homocysteine-induced cholesterol synthesis was examined.

Main Results:

  • Homocysteine significantly enhanced cholesterol production in HepG2 cells.
  • Elevated homocysteine also increased the secretion of apolipoprotein B-100.
  • The stimulatory effect on cholesterol synthesis was mediated by enhanced HMG-CoA reductase activity.

Conclusions:

  • Homocysteine promotes cholesterol synthesis by upregulating HMG-CoA reductase.
  • Increased cholesterol levels induced by homocysteine may drive higher apolipoprotein B-100 secretion.
  • These findings offer a plausible mechanism connecting hyperhomocysteinemia to atherogenesis and coronary artery disease.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...